The package leaflet provided to a patient with any drug product includes crucial information about a given therapy that can increase adherence and appropriate use of the product. To help make these leaflets as useful as possible for patients, in 2009, the European Commission published a new guideline on the readability of these labels with the aim of making them easier for patients to understand.
The package leaflet provided to a patient with any drug product includes crucial information about a given therapy that can increase adherence and appropriate use of the product. To help make these leaflets as useful as possible for patients, in 2009, the European Commission published a new guideline on the readability of these labels with the aim of making them easier for patients to understand.
A study newly published in BMJ Open sought to assess the readability of the package leaflets of biosimilars that are currently available in the EU market, and found that the leaflets for these drugs may not fulfill the role for which they were designed.
The cross-sectional analytical study included the 35 English-language package leaflets available online for biosimilars authorized for sale in the European Union as of August 2017. The products included hormones, insulins, granulocyte colony-stimulating factor (G-CSF) therapies, erythropoietins, low—molecular weight heparins, and monoclonal antibodies.
The investigators used the Flesch Index (which indicates how easy a text is to read) and the Flesch-Kincaid Index (which indicates a grade level needed to read a given text) to assess the readability of the leaflets.
They found that biosimilars’ leaflets were longer than those of reference biologics and, according to the Flesch Index, none of the leaflets was easy to understand, and all of them were more difficult to read than is recommended for health-related texts. There were significant differences between the sections of the leaflets in terms of length, with “possible side effects” containing the most text and “how to store” containing the least text. Readability of the sections also differed, with the “annex” of the labels (which generally contains information on how to handle the administration device) being the easiest to understand and “what [the product] is and what it is used for” being the hardest to understand.
Among the various types of biosimilars considered, anti—tumor necrosis factor (anti-TNF) therapies had the longest leaflets, while G-CSFs had the shortest. In terms of readability, heparins had the easiest leaflets to understand, while anti-TNFs had the hardest leaflets to understand.
“Excessive information in the package leaflets does not meet the requirements of patients,” write the authors, adding that “This becomes more important for biosimilars, the majority of which are prescribed in the treatment of serious diseases, such as cancer, as patients suffering from these conditions may experience a high degree of anxiety from the moment they receive the diagnosis.” A lack of readability, they say, could discourage patients from reading these inserts, or alarm patients who do read them, leading to reduced adherence.
In order to make these documents more likely to fulfill the function for which they are intended, readability tests should be applied to the leaflets prior to publication, say the authors.
Reference
Piñero-López MA, Figueiredo-Escribá C, Modamio P, Lastra CF, Mariño EL. Readability assessment of package leaflets of biosimilars. BMJ Open. 2019;9: e024837. doi: 10.1136/ bmjopen-2018-024837.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.